Edition:
United States

Keryx Biopharmaceuticals Inc (KERX.OQ)

KERX.OQ on NASDAQ Stock Exchange Capital Market

6.91USD
17 Oct 2017
Change (% chg)

$0.24 (+3.60%)
Prev Close
$6.67
Open
$6.69
Day's High
$6.95
Day's Low
$6.68
Volume
70,815
Avg. Vol
334,019
52-wk High
$8.37
52-wk Low
$4.14

Latest Key Developments (Source: Significant Developments)

KERYX BIOPHARMACEUTICALS SAYS MICHAEL ROGERS APPOINTED CHAIRMAN OF BOARD
Wednesday, 13 Sep 2017 04:10pm EDT 

Sept 13 (Reuters) - Keryx Biopharmaceuticals Inc ::KERYX BIOPHARMACEUTICALS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS.SAYS MICHAEL ROGERS APPOINTED CHAIRMAN OF THE BOARD.KERYX BIOPHARMACEUTICALS INC- MICHAEL ROGERS SUCCEEDS JOHN BUTLER WHO HAS RESIGNED FROM KERYX'S BOARD.  Full Article

Keryx Biopharmaceuticals Inc - co and Patheon Inc entered into a product agreement - SEC filing​
Friday, 1 Sep 2017 05:02pm EDT 

Sept 1 (Reuters) - Keryx Biopharmaceuticals Inc :Keryx Biopharmaceuticals Inc - co and Patheon Inc entered into a product agreement - SEC filing​.Keryx Biopharma - new ‍product agreement is in addition to two agreements entered under master agreement for Patheon's manufacture of Auryxia tablets​.Keryx Biopharmaceuticals Inc - ‍product agreement has an initial term ending December 31, 2024​.Keryx Biopharmaceuticals Inc - ‍ also product agreement will automatically renew after initial term for successive terms of two years each​.  Full Article

Keryx Biopharmaceuticals Q2 loss per share $0.77
Thursday, 27 Jul 2017 07:01am EDT 

July 27 (Reuters) - Keryx Biopharmaceuticals Inc ::Keryx Biopharmaceuticals announces second quarter 2017 financial results and increased 2017 u.s. Product sales guidance.Q2 loss per share $0.77.Q2 revenue $15.1 million versus I/B/E/S view $14.5 million.Q2 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.Keryx Biopharmaceuticals Inc - "Q2 gives us confidence to raise Auryxia's 2017 net product sales guidance to $62 to $66 million".Keryx Biopharmaceuticals Inc -sees full year 2017 net U.S. Auryxia product sales to $62 to $66 million from $56 to $60 million.Keryx Biopharmaceuticals Inc - cash and cash equivalents as of June 30, 2017 totaled $140.5 million compared to $111.8 million as of December 31, 2016..  Full Article

Keryx Biopharmaceuticals Q1 loss per share $0.21
Thursday, 4 May 2017 07:02am EDT 

May 4 (Reuters) - Keryx Biopharmaceuticals Inc ::Keryx Biopharmaceuticals announces first quarter 2017 financial results.Q1 loss per share $0.21.Q1 revenue $11.8 million versus I/B/E/S view $10.3 million.Q1 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.Sees for full year 2017 net u.s. Auryxia product sales of $56 to $60 million.Keryx biopharmaceuticals - q1 2017 net u.s. Auryxia product sales of $10.5 million versus $5.6 million in q1 of 2016.  Full Article

Keryx says FDA accepts application to expand use of Auryxia
Wednesday, 8 Mar 2017 07:30am EST 

Keryx Biopharmaceuticals Inc : Keryx biopharmaceuticals announces u.s. Fda filing acceptance of supplemental new drug application for auryxia® (ferric citrate) tablets . Keryx biopharmaceuticals announces u.s. Fda filing acceptance of supplemental new drug application for auryxia® (ferric citrate) tablets . Keryx biopharmaceuticals inc- prescription drug user fee act (pdufa) target action date for completion of fda's review is november 6, 2017 .Keryx biopharmaceuticals inc- ferric citrate was generally well tolerated and adverse events were consistent with its known safety profile.  Full Article

Keryx Biopharmaceuticals reports Q4 loss per share $0.32
Wednesday, 1 Mar 2017 07:00am EST 

Keryx Biopharmaceuticals Inc : Keryx Biopharmaceuticals announces fourth quarter and full year 2016 financial results . Q4 loss per share $0.32 . Q4 revenue $9.5 million versus I/B/E/S view $8.4 million .Q4 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.  Full Article

Keryx Biopharmaceuticals says most patients treated with ferric citrate achieved main goal in phase 3 trial
Thursday, 17 Nov 2016 10:31am EST 

Keryx Biopharmaceuticals Inc : Keryx Biopharmaceuticals announces multiple scientific presentations of phase 3 trial results of ferric citrate for iron deficiency anemia (IDA) in non-dialysis dependent chronic kidney disease (NDD-CKD) . Data demonstrate that in phase 3 trial, majority of patients treated with ferric citrate achieved the main goal . Pivotal phase 3 data showed potential of ferric citrate (auryxia) to treat IDA in adults with NDD-CKD .Ferric citrate was well tolerated with up to 16 weeks of dosing.  Full Article

Keryx Biopharmaceuticals announces third quarter 2016 financial results
Wednesday, 9 Nov 2016 07:01am EST 

Keryx Biopharmaceuticals Inc : Keryx Biopharmaceuticals announces third quarter 2016 financial results and provides corporate update . Q3 loss per share $0.39 . Q3 revenue $6.3 million versus I/B/E/S view $5.5 million .Q3 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

Keryx Biopharmaceuticals withdraws 2016 financial guidance
Monday, 1 Aug 2016 08:07am EDT 

Keryx Biopharmaceuticals Inc : Company withdraws its 2016 financial guidance . Company announces interruption in supply of Auryxia(ferric citrate) . Supply interruption does not affect safety profile of currently available Auryxia . Expects to make Auryxia available to patients when supply of Auryxia is back to adequate levels . Total revenues for quarter ended June 30, 2016 were about $9.3 million, compared with $2.5 million last year . Supply of Auryxia is expected to be back to adequate levels during Q4 of 2016 . Expects to file a supplemental new drug application (SNDA) with FDA late in Q3 of 2016 . Determined supply interruption is going to occur due to production-related issue in converting API to finished product at contract manufacturer . Current inventories of Auryxia are not sufficient to ensure uninterrupted patient access to this medicine . Issue resulted in variable production yields of finished drug product and company has exhausted its reserve of finished drug product . Says at this time, current inventories of Auryxia are not sufficient to ensure uninterrupted patient access to Auryxia . Says supply interruption does not affect safety profile of currently available Auryxia . Working with its existing manufacturer to resolve production-related issue and rebuild adequate supply . "We believe we are well positioned financially to manage through this interruption in supply of Auryxia".  Full Article

The Baupost Group L.L.C. reports 42.53 pct stake in Keryx Biopharmaceuticals - SEC filing
Wednesday, 1 Jun 2016 05:56pm EDT 

The Baupost Group, L.L.C. : The Baupost Group, L.L.C. reports 42.53% stake in Keryx Biopharmaceuticals Inc as of May 27, 2016 - SEC FILING .The Baupost Group, L.L.C. had earlier reported a 34.61%stake in Keryx Biopharmaceuticals Inc as of October 14, 2015.  Full Article